Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
62.1M
-
Number of holders
-
133
-
Total 13F shares, excl. options
-
53.2M
-
Shares change
-
+4.31M
-
Total reported value, excl. options
-
$1.22B
-
Value change
-
+$180M
-
Put/Call ratio
-
0.34
-
Number of buys
-
74
-
Number of sells
-
-74
-
Price
-
$23.00
Significant Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) as of Q1 2023
186 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock as of Q1 2023.
Protagonist Therapeutics, Inc - Common Stock (PTGX) has 133 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 53.2M shares
of 62.1M outstanding shares and own 85.57% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (4.6M shares), BlackRock Inc. (4.4M shares), BVF INC/IL (3.78M shares), VANGUARD GROUP INC (3.24M shares), FARALLON CAPITAL MANAGEMENT LLC (2.62M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.56M shares), JOHNSON & JOHNSON (2.45M shares), STATE STREET CORP (2.41M shares), Cormorant Asset Management, LP (1.7M shares), and MORGAN STANLEY (1.57M shares).
This table shows the top 133 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.